Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions by Burster, T. et al.
 
Repository of the Max Delbrück Center for Molecular Medicine (MDC) 
Berlin (Germany) 
http://edoc.mdc-berlin.de/ 
 
 
Published in final edited form as: 
Biochemical Pharmacology. 2007 Nov ; 74(10): 1514-1523 
doi: 10.1016/j.bcp.2007.07.037 
Elsevier (The Netherlands) ► 
 
 
 
 
 
 
 
 
 
 
 
Design of protease-resistant myelin basic 
protein-derived peptides by cleavage site 
directed amino acid substitutions 
Timo Burster, Viviana Marin-Esteban, Bernhard O. Boehm, Shannon Dunn, Olaf Rötzschke, 
Kirsten Falk, Ekkehard Weber, Steven H. L. Verhelst, Hubert Kalbacher, and Christoph Driessen 
Author Manuscript 
Design of protease-resistant myelin basic protein-derived 
peptides by cleavage site directed amino acid substitutions 
Timo Burster1, 2, 4, Viviana Marin-Esteban3, Bernhard O. Boehm4, Shannon Dunn5, Olaf 
Rötzschke3, Kirsten Falk3, Ekkehard Weber6, Steven H.L. Verhelst7, Hubert Kalbacher2,  and 
Christoph Driessen1, 2 
1 Department of Medicine II, University of Tübingen, Tübingen, Germany 
2 Medical and Natural Sciences Research Center, University of Tübingen, Tübingen, Germany 
3 Max-Delbrück-Center for Molecular Medicine, Berlin, Germany 
4 Division of Endocrinology and Diabetes, Department of Internal Medicine I, Ulm University, Ulm, 
Germany 
5 Department of Neurology & Neurological Science School of Medicine, Stanford University, Stanford, USA 
6 Institute of Physiological Chemistry, Martin Luther University Halle-Wittenberg, Halle, Germany 
7 Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA 
 
MDC Repository | http://edoc.mdc-berlin.de/8924/ 1 
 
ABSTRACT | Multiple Sclerosis (MS) is considered to be a T cell-mediated autoimmune disease. An 
attractive strategy to prevent activation of autoaggressive T cells in MS, is the use of altered peptide 
ligands (APL), which bind to major histocompatibility complex class II (MHC II) molecules. To be of clinical 
use, APL must be capable of resisting hostile environments including the proteolytic machinery of 
antigen presenting cells (APC). The current design of APL relies on cost- and labour-intensive strategies. 
To overcome these major drawbacks, we used a deductive approach which involved modifying 
proteolytic cleavage sites in APL. Cleavage site-directed amino acid substitution of the autoantigen 
myelin basic protein (MBP) resulted in lysosomal protease-resistant, high-affinity binding peptides. In 
addition, these peptides mitigated T cell activation in a similar fashion as conventional APL. The strategy 
outlined allows the development of protease-resistant APL and provides a universal design strategy to 
improve peptide-based immunotherapeutics. 
KEYWORDS | Antigen presentation/processing; Antigens/peptides/epitopes; Autoimmunity; MHC. 
ABBREVIATIONS | AEP, asparagine-specific endopeptidase; APC, antigen presenting cells; APL, altered 
peptide ligand; BLC, B-lymphoblastoid cell; Cat, cathepsin; EAE, experimental allergic encephalomyelitis; 
HPSEC, high performance size exclusion chromatography; HRP, horseradish-peroxidase; HLA, human 
leukocyte antigen; Ii, MHC class II invariant chain; MBP, myelin basic protein; MS, multiple sclerosis. 
 
 
1. Introduction 
Multiple Sclerosis (MS) is one of the most common 
autoimmune disorders in humans and is generally 
considered to be a T cell-mediated autoimmune 
disease. The activation of pathogenic self-reactive 
T cells ultimately results in destruction of the 
myelin sheath in MS patients. It is believed that 
MS is caused by a complex genetic trait to which a 
large number of genes contribute. For instance, 
human leukocyte antigens (HLA)-DRB1*1501, 
HLA-DRB5*0101 and HLA-DQB1*0602 have 
consistently been identified as conferring MS 
susceptibility [1]. Several indications point 
towards a role of myelin basic protein (MBP), a 
cytoplasmic protein of the myelin sheath, as a 
potential autoantigen in MS [2] and [3]. The 
immunodominant epitope has been localized as a 
minimal T cell epitope to MBP residue 85–99 
(MBP85-99) for HLA-DRB1*1501 and to MBP 
residue 116–123 (MBP116-123) for HLA-
DRB1*0401 [4]. MBP is also expressed in the 
thymus, and should lead to the elimination of 
MBP-specific T cells [5] and [6]. However, not all 
autoreactive T cells are deleted during thymic 
selection [7], so that T cells with the potential to 
recognize autoantigens, including myelin 
proteins, escape into the periphery [8]. Under 
certain conditions, such as viral infections [9], 
these T cells may become activated and cause 
autoimmune demyelination in the CNS. 
One particularly attractive treatment strategy for 
autoimmune diseases is to generate peptides, 
which can prevent T cell activation by forming a 
MHC II-peptide-T cell receptor (TCR)-tricomplex 
[10], [11] and [12]. Such altered peptide ligands 
(APLs), not only can mediate T cell receptor 
antagonism, they can also force T cells to secrete 
anti-inflammatory cytokines, and thereby reduce 
autoaggressive T cells (bystander suppression) 
[13]. MBP-derived APLs have already been tested 
in clinical trials [14], [15] and [16]. 
The caveat of peptide-based APL treatment is that 
the peptides can be degraded by proteases from 
blood serum or by the cathepsins (Cats)
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located in the MHC-class II antigen processing 
machinery. Cathepsins are divided into three 
classes according to the amino acid in their active 
center, the aspartate- (CatD and E), cysteine- (C1: 
CatB, C, F, H, L, S, V, X, and C13: asparagine specific 
endoprotease (AEP)) and serine proteases (CatG). 
It was shown that the immunodominant MBP 
epitope (MBP85-99) is efficiently degraded by 
several proteases, such as CatS, D, L, G and AEP 
[17], [18], [19] and [20]. Thus, protease-resistant 
APLs may be better suited to interfere with T cell 
activation, because as compared to naturally 
occurring ligands, protease-resistant APLs are 
likely to have a substantially greater half-life in the 
MHC II antigen processing compartment. Also, 
due to the protease-sensitivity of the natural 
ligands/natural peptides, it is difficult to transform 
such peptides into efficient APL. To overcome 
these major drawbacks, we applied a strategy to 
design a protease-resistant APL, by exchanging 
the amino acids at the targets of the major 
proteases, the result being a more stable APL. 
High-affinity binding to MHC molecules was 
maintained by keeping the anchor residues 
constant, and by avoiding the use of d-amino 
acids and instead incorporating methylated 
amino acids. This strategy shows promise of being 
used to prolong the biological half-life of peptide-
based immunotherapeutics resulting in a rational 
treatment of diseases. 
 
2. Materials and methods 
2.1. Peptide synthesis and purification 
Peptides were synthesized by the solid phase 
Fmoc-strategy on the multiple peptide 
synthesizer Syro II (MultiSynTech, Witten, 
Germany) by using a six-fold molar excess of 
amino acids. Activation and coupling were 
performed with TBTU, HOBT and NMM (Merck, 
Darmstadt, Germany). The crude peptides were 
purified by HPLC using a C18 column 125 × 8 
(Grom, Herrenberg, Germany) and analyzed by 
MALDI-TOF (G2025A, Hewlett-Packard, 
Waldbronn, Germany). 
 
2.2. Cells 
The human B-lymphoblastoid cell lines LD2B 
(HLA-DRB1*1501), WT-51 (HLA-DRB1*1501), MGAR 
(HLA-DRB1*1501) and myelomonocytoid cells 
THP-1 were cultured in complete RPMI 1640 
medium (10% FCS, 70 μg/ml antibiotics: 
gentamycin). The HLA-DR2-restricted MBP86-98 
chimeric T cell hybridoma 08073 (provides by L. 
Fugger) was cultured in DMEM medium 
supplemented with 5% FCS. 
2.3. Cathepsins and generation of lysosomal extracts 
and in vitro processing 
Lysosomal extracts were generated from B-
lymphoblastoid cells (WT-51) and 
myelomonocytoid cells (THP-1) by differential 
centrifugation and characterized as published 
before [21]. In brief, crude endosomal 
compartments were enriched by differential 
centrifugation from postnuclear supernatants, 
followed by a short exposure of the membrane 
pellet to water, which preferentially disrupts the 
membrane integrity of lysosomes due to their low 
osmotic resistance. This yielded virtually pure 
lysosomal extracts as judged by the distribution of 
cathepsin D, transferrin receptor and N-acetyl-
glucosaminidase. For in vitro processing, substrate 
solution (0.2 μg/μl peptide, 0.1 M citrate pH 5.0, 
2.5 mM DTT) was incubated with lysosomal 
fractions at 37 °C (2.6 μg of total protein). CatG was 
purchased from Sigma (Taufkirchen, Germany) 
and CatS, L, B, H, C, X and D from R and D Systems 
(Wiesbaden, Germany). 
 
2.4. Identification of processing products from 
MBP85-99 
Separation of in vitro processing products was 
achieved by microbore reverse phase HPLC using 
a C8 150 mm × 2 mm column (Wicom, 
Heppenheim, Germany) and mass spectrometry 
(MALDI-TOF G2025A, Hewlett-Packard, 
Waldbronn, Germany). 
 
2.5. Isolation of HLA-DRB1*1501 
Pellets of the B-lymphoblastoid cell line LD2B were 
disrupted by using lysis buffer (10 mM Tris, 
140 mM NaCl, 2% Triton, pH 7.8). After 
centrifugation the supernatant was filtered with a 
45 μm-filter, the probe was bound to a L243-
sepharose-column, washed (50 mM Na-
phosphate, 150 mM NaCl, 0.1% zwittergent, pH 8) 
and eluted (100 mM Na-phosphate pH 8, 0.1% 
zwittergent). The identity and purity of the 
isolated complexes was tested by SDS-PAGE and 
coomassie-staining under boiled/non-boiled 
conditions. 
 
2.6. Peptide-binding assay 
High performance size exclusion chromatography 
(HPSEC) was used for competition studies to 
reveal peptide binding to purified HLA-DRB1*1501 
essentially as described [22]. Briefly, solubilized 
HLA-DRB1*1501 molecules were incubated with 
N-terminally labeled (7-amino-4-methylcoumarin-
3-acetic acid, AMCA), allele specific peptide 
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(AMCA-MBP85-97) at pH 6.0 in the presence of 
detergent. Peptides (MBP85-99 or protease-
resistant peptides 0.1 μg/μl) were added as 
competitors and samples were analyzed by 
HPSEC. Both the fluorescence and UV signals were 
recorded, comparing the fluorescence intensity 
co-eluting with HLA-DRB1*1501 dimers in the 
presence/absence of competitor peptide. The 
fraction of competitor peptide that was bound to 
HLA-DRB1*1501 complexes was determined. 
 
2.7. T cell proliferation assay with MBP8698-specific T 
cells 
Human B-lymphoblastoid MGAR cells (5 × 104 /ml; 
HLA-DRB1*1501) were incubated with wt-peptide 
(10 μg/ml) and protease-resistant peptides 
(4 μg/ml, 20 μg/ml and 100 μg/ml) in the presence 
of the T cell hybridoma 08073 (5 × 104 cells) in a 
final volume of 200 μl medium DMEM, 5% FCS for 
24 h. Supernatants were then harvested and the 
released IL-2 was determined by measuring the 
3H-thymidine incorporation of the CTLL-2 cell line 
(5 × 104 ml−1) incubated in the supernatants for 
12 h. 
 
2.8. Western blot 
Anti-human cathepsin L antiserum was generated 
against affinity-purified human cathepsin L [23]. 
Cells were lysed in lysis buffer (10 mM Tris pH 7.5, 
150 mM NaCl, 0.5% NP-40), adjusted for equal 
total protein quantified by Bradford, resolved by 
SDS-PAGE and blotted using published conditions 
[24]. 
 
2.9. Determination of cathepsin-activity with 
fluorogenic substrate 
Hydrolysis of 200 μM of the CatG-sensitive 
fluorogenic substrate Z-AAPF-AMC (Bachem, Weil 
am Rhein, Germany) was measured with or 
without preincubation with the CatG-specific 
inhibitor I (Calbiochem, Schwalbach, Germany) 
after incubation with 5 ng of CatG (Sigma, 
Germany), or 2.6 μg lysosomal extracts from 
WT51, THP-1 and CD14-cells in 100 μl assay buffer 
(0.1 M Tri/HCl pH 8.0, 0.5 M MgCl2). The 
fluorogenic substrate MOCA-GKPILFFRLK-(Dnp)-
D-R-NH2 (Bachem, Weil am Rhein, Germany) 
(3 μM) was used to determine CatD/E activity in 
reaction buffer (150 mM sodium-acetate buffer pH 
4.0) with and without pepstatin A (Bachem, Weil 
am Rhein, Germany). The substrate turnover was 
determined by measuring the emission at 480 nm 
(excitation at 360 nm) (Tecan SpectraFluor, 
Crailsheim, Germany). 
2.10. Affinity-labeling of active cysteine proteases 
Lysosomal extracts (1.3 μg) were incubated with 
reaction buffer (0.1 M citrate pH 5.0, 50 mM DTT) 
in the presence of DCG-04 [25] for 1 h at room 
temperature. Reactions were terminated by 
addition of SDS reducing sample buffer and 
immediate boiling. Samples were resolved by 12% 
SDS-PAGE, blotted on a PVDF-membrane and 
active polypeptides visualized using streptavidin 
HRP and the ECL-detection kit [23]. 
 
3. Results 
3.1. In vitro processing of MBP85-99 with isolated 
cathepsins 
In ►Fig.1A we compared two possible approaches 
for generating a protease-resistant peptide: the 
conventional random amino acid substitution 
method versus to a novel systematic cleavage site-
directed amino acid substitution approach. The 
conventional approach generates considerably 
more peptide permutations than the systematic 
substitution. For this systematic site-directed 
strategy, it was essential to distinguish the exact 
cleavage site of a given cathepsin in order to 
substitute different amino acids until the 
cathepsin cleavage site was eliminated. We 
simultaneously preserved the HLA-DRB1*1501 
binding anchor while increasing the peptide's 
protease resistance. These peptide alterations lead 
to reduce T cell activation. ►Fig.1B (left panel), 
illustrates the binding of HLA-DRB1*1501 to the 
immunodominant T cell epitope MBP85-99 
(designated wild type (wt)-peptide in the 
remainder) with the binding anchors valine at 
position 87 (V87), phenylalanine at position 90 
(F90), and isoleucine at position 93 (I93). In order 
to determine the positions at which isolated 
cathepsins (Cats), such as CatB, C, D, G, H, L, S and 
X, can digest soluble wt-peptide, we incubated wt-
peptide with individual proteases, followed by 
identification of the resulting fragments by HPLC 
and mass spectrometry. We found that the serine 
protease CatG digested wt-peptide between 
phenylalanine 90 and lysine 91 (90FK91) as 
summarized in ►Fig.1B (right panel). The 
endoprotease CatS was proteolytically active 
between histidine 88 and phenylalanine 89 
(88HF89), as well as between lysine 91 and 
asparagine 92 (91KN92). Likewise the 
endoprotease CatL showed major cleavage sites 
between lysine 91 and asparagine 92 (91KN92). 
CatB, which is known to have 
carboxyexopeptidase activity, removed two amino 
acids at the carboxy terminus of wt-peptide 
between arginine 97 and threonine 98 (97RT98). 
While the aminopeptidase CatH removed 
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individual amino acids from the N-terminus of the 
wt-peptide, CatC with its dipeptidyl-peptidase 
activity cleaved N-terminal dipeptides. The 
carboxypeptidase CatX did not cause C-terminal 
hydrolysis of wt-peptide, possibly due to the 
presence of the C-terminal proline. It is perhaps 
noteworthy that when we incubated peptide 
Mu12, which contains a lysine at position 99 (K99), 
with CatX, this amino acid was removed (data not 
shown). The aspartate protease CatD with its 
specificity preference between hydrophobic 
residues, digested the wt-peptide between 
phenylalanine 89 and phenylalanine 90 (89FF90). 
 
3.2. Determination of cathepsin dustribution of BLC 
and THP-1 
Since different types of APC contain distinct sets 
of proteases, we generated lysosomal fractions 
from the B lymphoblastoid cells (BLC) and 
myelomonocytoid cell line THP-1 obtained by 
differential centrifugation and hypotonic lysis [21]. 
To compare the sets of active papain family 
cysteine proteases between both types of cells 
(BLC and THP-1), respective lysosomal proteases 
were incubated with the biotinylated protease 
activity-restricted probe DCG-04, which binds 
covalently to active cysteine proteases of the 
papain family, allowing the direct visualization of 
active cathepsin polypeptides via a biotin moiety. 
We detected active CatX (37 kDa), CatB (33 kDa), 
CatH (29 kDa) and CatS (28 kDa) in THP-1, BLC as 
well as CD14+ cells (►Fig.2A, upper panel) 
(►Fig.2A, upper panel), in agreement with 
published data [23]. THP-1-derived lysosomal 
proteases contained more CatB, as well as 
additional active polypeptides with a molecular 
mass around 35 and 40 kDa. THP-1 cells also 
contained sizable amounts of mature CatL. In 
contrast to THP-1, DCG-04 labeled human CatL in 
BLC-derived lysosomal proteases only poorly, as 
assessed by Western blot (►Fig.2A, lower panel). 
CatL was detected abundantly as pro- (32 kDa) 
and mature form (25 kDa) in THP-1-derived 
lysosomal proteases. 
Aspartate protease activity in THP-1, BLC and 
CD14 cells (presumably combined CatD/E-activity) 
was assessed by measuring the turnover of the 
fluorescent substrate MOCA-GKPILFFRLK-(Dnp)-D-
R-NH2, in the presence or absence of the 
respective inhibitor pepstatin A (PepA). Activity 
was markedly higher in THP-1-derived lysosomal 
proteases, compared to BLC- and CD14-derived 
controls (►Fig.2B, upper panel). CatG activity was 
assessed in a similar fashion using the substrate Z-
AAPF-AMC, and verified by specific inhibition. 
While measurable CatG activity was absent from 
BLC cells, it was present in THP-1, as well as in 
CD14 controls (►Fig.2B, lower panel). Thus, 
compared to BLC, lysosomal extracts from THP-1 
cells contain markedly higher amounts of 
cysteine-type endo- and exopeptidases (CatB, 
CatL), serine proteases (CatG) as well as aspartate 
proteases (presumably CatD and CatE), 
representing an extremely hostile environment for 
the integrity of short linear peptides. 
 
3.3. Generation of a protease-resistant peptide based 
on MBP85-99 
Subsequently, we synthesized MBP85-99-based 
protease-resistant peptides, which withstand 
proteolytic activity for at least 24 h, using natural 
and non-natural amino acids and eliminated 
protease cleavage sites in a stepwise fashion. To 
this end, the amino acid positions that are 
expected to determine the cleavages of wt-
peptide by isolated cathepsins as observed above 
(e.g. 88HF89 for CatS, 90FK91 for CatG, C-and N-
terminal amino acids for CatC, H and B) were 
subsequently replaced by amino acids that were 
less likely to result in protease attack at its 
dominant cleavage site. At the same time, we 
maintained HLA-DRB1*1501 anchors. Altered 
peptides (Mu1-Mu20) were incubated with 
lysosomal proteases from both human BLC and 
THP-1 cells, to address differences in the action of 
the two protease mixes. We used mass 
spectrometry to identify the resulting proteolytic 
fragments, and quantified the ratio between the 
amounts of intact peptides at the start of the 
incubation period with that after 24 h of 
incubation with lysosomal proteases by HPLC. 
►Fig.2C (left panel) summarizes the proteolytic 
patterns and protease stability of 10 selected 
altered peptides (Mu1-Mu20) incubated with BLC-
derived lysosomal proteases. 
We eliminated the cleavage site of AEP and CatD 
in Mu1, however, these changes did not influence 
the amounts of intact peptide retrieved after 24 h 
of incubation with BLC-derived lysosomal 
proteases, compared to the wt-peptide. We then 
substituted amino acids in position K91 and I92 by 
P91 and P92, and added two prolines at the C-
terminus (Mu4) or we synthesized a peptide with 
protecting groups (Mu11) such as Z-alanine (Z-A) 
and amide-bound lysine (K-NH2 99) for 
exoprotease protection. Not until we used d-
amino acids (D-P85, D-V86), was complete 
protection of the amino-terminus observed 
(Mu14, 15, 18, 20) and D-T98 prevented 
degradation from the carboxy-terminus (Mu12, 13, 
15, 17, 20). 
►Fig.2D (left panel) shows relative amounts of the 
intact original peptide after 24 h of incubation 
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with lysosomal proteases from BLC, as quantified 
by HPLC. We detected only traces of residual full-
length peptide from the wt-peptide, as well as 
from Mu1. In contrast to wt-peptide, Mu4, 11, 12, 
13, 14 showed an increase in protease resistance 
(30–70% intact peptide after 24 h of digest, 
compared to ~3% with the wt-peptide). 
Significant protease protection was achieved 
(>90%) when both N and C-terminal exoprotease 
cleavage was blocked by the introduction of 
either d- or methylated amino acids at both 
preterminal positions (Mu15, 17, 18, and 20). 
►Fig.2C and D (right panel) summarizes the 
different cleavage sites when we incubated 
protease-resistant peptides with THP-1-derived-
lysosomal proteases as compared to BLC. Mu11, 
12, 15, 17 and 18 were not resistant against the 
lysosomal protease pool present in THP-1 cells. 
The protease-lability of Mu17 and 18 in this 
setting was found to be most likely due to one or 
two single proteases not present in BLC. To 
address which proteases are capable of digesting 
Mu18, we incubated Mu18 with different isolated 
cathepsins and found that only CatL was still able 
to cleave Mu18 between K91 and S92 (data not 
shown). Based on this information we synthesized 
Mu20 which incorporates methylated amino 
acids, such as isoleucine at position 93 (Me-I93), 
valine at 86 (Me-V86) and thyrosine at 90 (Me-Y90) 
to both eliminate the CatL cleavage site and 
increase binding to HLA-DRB*1501. Mu20 resisted 
degradation by lysosomal proteases from both 
BLC and THP-1 cells in vitro for at least 24 h by 
more > 80%. 
 
3.4. Amino acids next to anchor residues interfere 
with binding of MBP85-99 to HLA-DRB1*1501 
Peptide binding to MHC class II molecules is 
mediated by the interaction of the anchor 
residues of the peptide with the binding groove 
of MHC class II molecules. To quantify peptide 
binding we performed a competition assay [22]. 
Fluorescent labeled MBP85-97 peptide (AMCA-
MBP85-97) was loaded onto HLA-DRB1*1501. 
Subsequently, protease-resistant peptides were 
added at an equimolar ratio and binding was 
analyzed by high performance size exclusion 
chromatography with simultaneous fluorescent 
and UV-detection to determine which portion of 
the fluorescent peptide co-eluted with the MHC 
class II complex. Using this assay, different peptide 
permutations were compared in order to define 
which amino acid-charges would allow 
competition of wt-peptide from binding to HLA-
DRB1*1501. We found that the exchange of 
asparagine 91 (N91) to glutamine 91 (Q91) (MuQ) 
reduced HLA-DRB1*1501 peptide competition 
capacity to 50%, aspartic acid 91 (D91, MuD) to 
~60%, whereas serine 91 (S91, MuS) had no 
negative effect on competition of the 
immunogenic peptide (►Fig.3A). In contrast to d-
valine 86 (D-V86, Mu15D-V) methylated valine at 
86 (Me-V86, Mu15Me-V) also did not grossly 
interfere with binding to HLA-DRB1*1501. All of 
this suggested that amino acids adjacent to the 
anchor residues are also important for binding to 
HLA-DRB*1501. 
Having generated protease-resistant peptides, we 
wanted to know whether these peptides would 
also bind to HLA-DRB1*1501. Mu1, Mu4, Mu11, 
Mu12 as well as Mu15 and Mu17 competed poorly 
with the AMCA-MBP85-97 for binding to HLA-
DRB1*1501, compared to Mu13, Mu14, Mu18 and 
Mu20, which efficiently replaced the AMCA-
MBP85-97 from the HLA-DRB1*1501 binding 
groove (as shown in (►Fig.3B). 
 
3.5. Protease-resistant peptides inhibit MBP86-98-
specific T cell activation 
Self-reactive T cells lead to autoimmunity. 
Therefore, we tested the effect of the protease-
resistant peptides on the MBP-specific T cell 
response in vitro. We incubated a HLA-DRB1*1501-
positive B cell line MGAR simultaneously with 
10 μg/ml wt-peptide and serially increasing 
amounts of protease-resistant peptides, followed 
by the addition of MBP86-98 specific T cells. 
Secreted IL-2 was quantified by assessing the 
incorporation of [3H] thymidine (cpm) by CTLL-2 
cells grown in the respective culture supernatants. 
As expected, in the absence of competing 
protease-resistant peptides, significant T cell IL-2 
secretion was detected (►Fig.4). Addition of Mu1, 
which was not protease-resistant and had a low 
affinity to HLA-DRB1*1501, resulted in only 
modest reduction of T cell IL-2 secretion at 
equimolar concentrations. Mu13 and Mu14 both 
showed a binding affinity similar to the wt-
peptide, however, they were significantly more 
protease resistant. As a result, they reduced T cell 
IL-2 secretion already at sub-equimolar 
concentrations, indicating that introducing 
protease-resistance is indeed a method to 
augment the effect of APL. In contrast, Mu18, 
which was resistant to BLC-derived lysosomal 
proteases, but bound poorly, showed significant 
inhibition of T cell IL-2 secretion only when added 
at high concentrations. Mu20, the most protease-
resistant peptide with strong HLA-DRB1*1501-
binding also inhibited T cell proliferation when 
cultured simultaneously with wt-peptide and is 
therefore an attractive prototype candidate to 
block MBP-specific T cell proliferation. 
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4. Discussion 
We show that the design of protease-resistant 
peptides by cleavage site directed amino acid 
substitution results in virtually complete 
resistance to lysosomal proteases derived from 
both B lymphoblastoid cells and 
myelomonocytoid cells THP-1. Altered peptide 
ligands are prone to degradation in a proteolytic 
environment. We address this major obstacle by 
generating protease-resistant peptides based on a 
multiple sclerosis- (MBP85-99) autoantigen, which 
antagonized MBP85-99-specific T cell activation in 
vitro. 
We systematically eliminated endoprotease 
cleavage sites based on the proteolytic patterns 
obtained from isolated proteases. The subset of 
cathepsins used in this digest represents the 
major endocytic proteases known to date. 
Although this list is not necessarily complete, the 
proteases analysed are responsible for the 
majority of cleavage sites found when peptides 
are incubated with lysosomal proteases, arguing 
that functionally, the most important proteases 
are covered by this selection. We protected the N- 
and C-terminal ends of the MBP85-99 peptide by 
adding non-natural amino acids in the 
preterminal position, and at the same time 
optimized binding to HLA-DRB1*1501 by 
changing amino acids in the respective anchor 
positions (Mu13, 14, 17, 18 and 20). Interestingly, 
at the TCR contact sites (F89, K91, P96), the 
exchange of one amino acid (K91 to P91), as 
shown for Mu13, 14, 15 and 20, was sufficient to 
antagonize T cell proliferation. While d-amino 
acids increased the stability of the peptide in a 
proteolytic environment, binding affinity to HLA-
DRB1*1501 appeared to be reduced. However, 
when we used methylated amino acids at the 
same position, the resulting peptides were not 
only protease-resistant, which is in agreement 
with published data [10], but also bound to HLA-
DRB1*1501 with affinity comparable to natural 
amino acids. Thus, the use of methylated amino 
acids represents a method for generating a 
protease-resistant peptide without losing binding 
affinity to MHC class II molecules. 
Although bioinformatic tools can be used to 
generate peptides that are capable of resisting 
proteolytic activity with results that are 
comparable to our approach. The strategy that we 
used involves substantially lower amounts of time 
and resources. This is especially important, 
because the approach has to be tailored to 
different HLA haplotypes and autoantigens, which 
would require extensive computer modelling 
resources. 
Even if an APL is not loaded on MHC class II within 
the endocytic compartment, but rather at the cell 
surface, as may be the case for peptide 
competition of the MBP immunogenic peptide, 
such an APL needs protection from proteolysis, as 
shown by resistance to the lysosomal protease 
contents of THP-1 cells. The Mu20 peptide 
generated by our approach can withstand 24 h of 
incubation time in a concentrated mixture of 
cysteine-, aspartate- and serine-proteases of the 
endoprotease and exoprotease type. Several 
proteases of the bloodstream, such as serine 
proteases (for instance CatG or the coagulation 
factor thrombin), limit the potential use of APL in 
vivo. Therefore, any APLs used must also be able to 
withstand the proteolytic components of the 
blood. We incubated Mu20 with human blood 
serum for 24 h and found that Mu20 was stable 
from degradation by protease activity, suggesting 
a prolonged stability during in vivo use (data not 
shown). 
Tselios et al. have reported an improved protease 
stability for cyclic analogous of the 
immunodominant epitope MBP87-99 (cyclo (87–
99) [Arg91 Ala96] MBP87-99) that translated into 
better T cell inhibition. Cyclo (87–99) [Arg91 Ala96] 
MBP87-99 bound to HLA-DR4 molecules, inhibited 
EAE in Lewis rats as well as suppressed CD4+ T cells 
from MS patients and was therefore suggested as 
a potential therapeutic treatment for MS [26]. 
These cyclic analogues demonstrated less 
protease-resistance when lysosomal proteases 
from THP-1 were used as compared to the linear 
protease-resistant peptides synthesized by the 
method described here (data not shown). 
Glatiramer acetate (copaxone), a random synthetic 
amino acid (poly [Y, E, A, K]), which potently binds 
to HLA-DRB1*1501, was originally designed to 
induce EAE, but was later found to block the 
induction of EAE [27] and [28]. It was subsequently 
tested in Multiple Sclerosis patients and was found 
to be a successful therapeutic in clinical trials [29]. 
Although copaxone is a peptide-based 
therapeutic, it is very likely to suffer from 
proteolytic destruction when administered 
systemically or even internalized into endocytic 
compartments of APC, with or without prior 
binding to MHC II on the cell surface. To 
demonstrate this, we incubated copaxone with 
lysosomal extracts from THP-1. This resulted in its 
complete digestion after eight hours (data not 
shown). Introduction of appropriate non-natural 
methylated amino acids might prolong the 
biological half live of copaxone, improve its 
efficacy, or at least reduce the 20 mg daily 
injection recommended for the treatment of MS 
patients. 
Burster T et al. 
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Cleavage site-directed amino acid substitution 
strategy entails a relatively few number of steps, 
and incorporates published knowledge regarding 
the major immunogenic peptide and its binding 
preferences to the most relevant MHC II. Such 
information is now available for a number of MHC 
II-associated autoimmune diseases. Thus, it should 
be possible to transfer this strategy to other 
autoimmune diseases, bypassing the need for 
technically challenging, time-consuming and 
expensive molecular modelling strategies that 
aim for a similar goal. 
Low stability and protease destruction are a 
common problem for virtually all small, peptide-
based types of drugs, including APL and those 
used for peptide vaccinations. We demonstrated 
that virtually entirely protease-resistant peptides 
can be designed and synthesized, using a 
relatively simple deductive approach. These 
peptides retain the ability of binding HLA-
DRB1*1501 and can be used to suppress MBP-
specific T cell activation. The transfer of the 
knowledge of the approach presented here is 
promising to other peptide-based 
immunotherapies currently limited by proteolytic 
destruction. 
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►Fig.1. Generation of MBP85-99-derived peptides resistant to the proteolytic activity of proteases. (A) 
Comparison of a classical random amino acid substitution method to the here presented cleavage site-
directed amino acid substitution strategy, for the generation of protease-resistant peptides. The first 
approach will require the synthesis of 1520 or 1220 peptides (using only natural amino acids) to identify 
those protease-resistant whereas the second approach we designed only 20 peptides: 11 only with 
natural amino acids and nine with modified amino acids, to generate MBP85-99-derived peptides highly 
resistant to lysosomal proteases. (B) In vitro processing of MBP85-99-peptide (wt-peptide) with isolated 
cathepsins. Left panel shows a cartoon depicting the anchor residues of MBP85-99 to HLA-DRB1*1501: 
valine at position 87 (V87), phenylalanine at position 90 (F90), and isoleucine at position 93 (I93). The right 
panel shows a summary of digestion pattern using wt-peptides that were incubated with different 
isolated cathepsins and the resulting fragments were identified by HPLC and mass spectrometry. 
Burster T et al. 
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►Fig.2. Generating MBP85-99-derived protease-resistant peptides. (A) Lysosomal proteases from purified 
B lymphoblastoid cells (BLC), myelomonocytoid cells THP-1 and CD14-derived lysosomal proteases were 
normalized for total protein content, labeled with the biotinylated activity-based probe DCG-04, resolved 
by SDS-PAGE and papain-like cysteine proteases were visualized by streptavidin HRP-blot. CatX, B, H, S 
and C were detected as active cysteine proteases (upper panel). In addition, CatL-levels were assessed by 
performing CatL-specific Western blot (lower panel). (B) CatD/E-activity was determined at pH 4.0 by 
measuring the turnover of the fluorogenic substrate MOCA-GKPILFFRLK-(Dnp)-D-R-NH2 in lysosomal 
proteases from BLC, THP-1 and CD14 (upper panel). CatG-activity was measured by using Z-AAPF-AMC at 
pH 8.0 and specified with the specific CatG-inhibitor I (lower panel). Data are representative of two 
independent experiments and each was done in duplicates. PepA: pepstatin A and inh: CatG-specific 
inhibitor I. (C) Altered peptides (Mu1-Mu20) were incubated for 24 h at 37 °C with BLC (left panel) or THP-
1 (right panel)-derived lysosomal proteases. To eliminate AEP cleavage site asparagine to glutamine in 
position 92 (N92 to Q92) was exchanged and phenylalanine to proline 89 (F89 to P89) to abolish 
proteolytic activity by CatD (Mu1). Proline amino acids at the C-terminus (Mu4) and using protecting 
groups (Mu11) such as Z-alanine (Z-A) and amide-bound lysine (K-NH2 99) were used to reduce 
exoprotease activity. To protect proteolytic attack at the N-terminus or C-terminus, respectively, d- 
(Mu12, 13, 14, 15, 17, 18, 20) and methylated amino acids (Mu20) were synthesized. (D) The relative 
amounts of intact peptides remaining after lysosomal-derived protease digestion were quantified by 
HPLC in percent. Three independent experiments are shown. Blue amino acid letters indicate anchor 
residues, in red substituted amino acids and arrows indicate protease cleavage sites. 
Burster T et al. 
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►Fig.3. Protease-resistant peptides bind to HLA-DRB1*1501 with affinity similar to MBP85-99. (A) 
Peptides with single exchanged-, d- or methylated amino acids were incubated for 24 h at 37 °C with BLC-
derived lysosomal proteases and the proteolytic intermediates were analyzed by mass spectrometry 
(arrows show the cleavage sites of lysosomal proteases). Peptide-binding to HLA-DRB1*1501 were 
performed by a competition assay. Fluorescent labeled MBP85-97 peptide (AMCA-MBP85-97) was 
preloaded onto HLA-DRB1*1501 molecules and was competed by altered peptide ligands at equimolar 
ratio and analyzed by high performance size exclusion chromatography (HPSEC). (B) Protease-resistant 
peptides (Mu1-Mu20) were added to AMCA-MBP85-97-HLA-DRB1*1501 complexes at equimolar ratio 
and analyzed by HPSEC. 
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►Fig.4. Protease-resistant peptides inhibit MBP86-98-specific T cell proliferation. HLA-DRB1*1501-
positive B lymphoblastoid cells MGAR was incubated with 10 g/ml MBP85-99 and increasing amounts of 
protease-resistant peptides (4, 20 and 100 g/ml), followed by the addition of MBP85-99-specific T cells. 
IL-2 U/ml levels were measured by CTLL-2 cells grown in the culture supernatants. One of three 
experiments with similar results is shown. Ag: antigen. 
